Catalyst Pharmaceuticals (CPRX) traded flat today, closing at $31.49 with negligible movement, as investors digested news that Italys Angelini Pharma has officially completed its $4.1 billion takeover of the company. This marks a major milestone, effectively ending CPRXs run as an independent Nasdaq-listed biotech.
Shareholder Approval (July 10, 2026): CPRX shareholders cleared the merger earlier this month, paving the way for todays completion.
No More Independent Trading: CPRXs days as a standalone Nasdaq biotech are over.
